Skip Navigation
Menu
Editorials |19 September 2017

Continuous Glucose Monitoring in Patients With Type 2 Diabetes Receiving Insulin Injections: Does This Mean Continuous Glucose Monitoring for Everyone?

Vanessa Arguello, MD; Matthew Freeby, MD

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
This article was published at Annals.org on 22 August 2017.
  • From David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California.

    Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M17-2121.

    Requests for Single Reprints: Vanessa Arguello, MD, David Geffen School of Medicine at UCLA, 1245 16th Street, Suite 307, Santa Monica, CA 90404; e-mail, varguello@mednet.ucla.edu.

    Current Author Addresses: Dr. Arguello: David Geffen School of Medicine at UCLA, 1245 16th Street, Suite 307, Santa Monica, CA 90404.

    Dr. Freeby: David Geffen School of Medicine at UCLA, 200 Medical Plaza Driveway, Suite 530, Los Angeles, CA 90095.

×
FULL TEXT
Despite advances in care over the past 2 decades, nearly half of persons living with type 2 diabetes mellitus (T2DM) have uncontrolled disease and are at high risk for complications (1). New technologies aimed at treatment, including advancements in glucose monitoring, may affect control and reduce hypoglycemia risk. Almost 3 decades has passed since the U.S. Food and Drug Administration approved the first continuous glucose monitoring (CGM) system. These devices, introduced in 1999, were uncomfortable, inaccurate, and difficult to use. Now, compact devices can provide consistent and timely data by measuring interstitial fluid every 5 minutes, correlating well with plasma glucose levels; they transmit current and predicted glucose values to cell phones and other devices, providing real-time user feedback. As a result, real-time CGM (RT-CGM) enables both patients and physicians to visualize daily glucose patterns, including variations after meals, exercise, and illness and in response to changes in treatment regimens. Furthermore, device alerts notify users and their support systems of impending hypoglycemia and hyperglycemia.
FULL TEXT
PDF
Not Available
Citations
Citation

Arguello V, Freeby M. Continuous Glucose Monitoring in Patients With Type 2 Diabetes Receiving Insulin Injections: Does This Mean Continuous Glucose Monitoring for Everyone?. Ann Intern Med. 2017;167:436–437. doi: 10.7326/M17-2121

Download citation file:

© 2019

×
Permissions

Published: Ann Intern Med. 2017;167(6):436-437.

DOI: 10.7326/M17-2121

Published at www.annals.org on 22 August 2017

©
2017 American College of Physicians
1 Citations

Related Articles
Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial
Annals of Internal Medicine; 167 (6): 365-374
Annals for Educators - 19 September 2017
Annals of Internal Medicine; 167 (6): ED6
New Modes of Insulin Administration: Do They Have a Role in Clinical Diabetes?
Annals of Internal Medicine; 105 (1): 126-129
In high-risk T1DM, real-time continuous glucose monitoring vs self-monitoring reduced hypoglycemic events
Annals of Internal Medicine; 168 (10): JC53
View MoreView Less

Journal Club
In high-risk T1DM, real-time continuous glucose monitoring vs self-monitoring reduced hypoglycemic events
Annals of Internal Medicine; 168 (10): JC53
Protocol-based nurse management of type 2 diabetes did not differ from usual GP care for HbA1c levels
Annals of Internal Medicine; 155 (6): JC3-7
View MoreView Less

Related Point of Care
Type 2 Diabetes
Annals of Internal Medicine; 162 (5): ITC1
Type 2 Diabetes
Annals of Internal Medicine; 152 (5): ITC3-1
Type 2 Diabetes
Annals of Internal Medicine; 146 (1): ITC1-1
Diabetic Ketoacidosis
Annals of Internal Medicine; 152 (1): ITC1-1
View MoreView Less

Related Topics
Cardiology
Coronary Risk Factors
Diabetes
Endocrine and Metabolism

Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism.

PubMed Articles
Hyperglycemia and Glucose Variability Are Associated with Worse Brain Function and Seizures in Neonatal Encephalopathy: A Prospective Cohort Study.
J Pediatr 2019.
Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence.
Metabolism 2019.
View More

Results provided by: PubMed

CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×